Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06127160 · ClinicalTrials.gov registry record · Phase 4
Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis
A Phase 4 study, sponsored by Brett A Faine.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT06127160: Completed Phase 4 study, sponsored by Brett A Faine.
NCT06127160 is a Phase 4 study that has completed, run by Brett A Faine. The registered enrollment target is 35 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06127160, a Phase 4 study, has completed, sponsored by Brett A Faine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
This pilot study will randomize 40 female patients with acute uncomplicated pyelonephritis to receive standard duration of therapy versus patient-directed antimicrobial duration (PDAD). The primary objectives of this pilot trial are to determine the feasibility and safety of conducting a full-scale multi-center randomized controlled trial.
Primary Outcome
Percentage of participants that complete all study activities and follow-up through 90 days
Interventions
- DRUG Cephalexin
- DRUG Cephalexin or placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-06-04 |
| Est. Completion | 2025-08-29 |
| Phase | Phase 4 |
What the finished NCT06127160 record still lists
NCT06127160 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Cephalexin is the first listed.
NCT06127160 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06127160 about?
NCT06127160 is a clinical study titled "Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis". This pilot study will randomize 40 female patients with acute uncomplicated pyelonephritis to receive standard duration of therapy versus patient-directed antimicrobial duration (PDAD). The primary objectives of this pilot trial are to determine the feasibility and safety of conducting a full-scale ...
What is the current status of trial NCT06127160?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2024-06-04. Estimated completion is 2025-08-29.
What interventions are being tested in trial NCT06127160?
The interventions under investigation include: Cephalexin (DRUG), Cephalexin or placebo (DRUG).
Who is sponsoring clinical trial NCT06127160?
This trial is sponsored by Brett A Faine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06127160's enrollment target sits among peer trials
35 1506th of 2000 higher than 481 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI